ArticleAnnals of neurology2016
Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease.
Article in Annals of neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 2 syntheses or guidelines pooled it, 102 citations in OpenAlex.
- Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: A meta-analysis.Neurology · 2018Pooled it
- Detectable Neuropsychological Differences in Early Preclinical Alzheimer's Disease: A Meta-Analysis.Neuropsychology review · 2017Pooled it
- A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.Nature medicine · 2021Trial
- Cerebrospinal Fluid Biomarker Ratio Concordance with Amyloid Positron-Emission Tomography: A Diagnostic Test Accuracy Meta-analysis.Neurology and therapy · 2026Article
- The Machine Learning Classification of Retinal Ganglion Cell Dendritic Texture in a 3xTg-Alzheimer's Disease Mouse Model.Diagnostics (Basel, Switzerland) · 2026Article
- Comparing the predictive value of plasma p-tau217 and CSF biomarkers (p-tau181, Aβ42) using amyloid positron emission tomography in Alzheimer's continuum.Research square · 2025Article
- Combination of amyloid and FDG PET for the prediction of short-term conversion from MCI to Alzheimer´s disease in the clinical practice.European journal of nuclear medicine and molecular imaging · 2025Article
- BrainVAE: Exploring the role of white matter BOLD in preclinical Alzheimer's disease classification.bioRxiv : the preprint server for biology · 2025Article
- Bundle-wise functional connectivity density and fractional amplitude of low-frequency fluctuations decrease in white matter in preclinical Alzheimer's disease and are associated with Aβ levels and cognition.Proceedings of SPIE--the International Society for Optical Engineering · 2025Article
- Exploring the Link Between Periodontitis and Alzheimer's Disease-Could a Nanoparticulate Vaccine Break It?Pharmaceutics · 2025Review
- Fast Declining Prediction in Alzheimer's Disease from Early Clinical Assessment.Current neuropharmacology · 2025Observational
- Elevated locus coeruleus metabolism provides resilience against cognitive decline in preclinical Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- New Research on Biomarkers in Alzheimer's Continuum.Reviews on recent clinical trials · 2025Review
- Reductions in the white-gray functional connectome in preclinical Alzheimer's disease and their associations with amyloid and cognition.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Serum metabolome profiling in patients with mild cognitive impairment reveals sex differences in lipid metabolism.bioRxiv : the preprint server for biology · 2024Article
- Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset.Annals of neurology · 2024Article
- Plasma Biomarkers as Predictors of Progression to Dementia in Individuals with Mild Cognitive Impairment.Journal of Alzheimer's disease : JAD · 2024Article
- Proteomics of brain, CSF, and plasma identifies molecular signatures for distinguishing sporadic and genetic Alzheimer's disease.Science translational medicine · 2023Article
- Gut microbiome composition may be an indicator of preclinical Alzheimer's disease.Science translational medicine · 2023Article
- PET molecular imaging for pathophysiological visualization in Alzheimer's disease.European journal of nuclear medicine and molecular imaging · 2023Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveDeposition of amyloid β (Aβ)-containing plaques as evidenced by amyloid imaging and cerebrospinal fluid (CSF) Aβ1-42 (Aβ42) is an early indicator of preclinical Alzheimer disease (AD). To better understand their relationship during the earliest preclinical stages, we investigated baseline CSF markers in cognitively normal individuals at different stages of amyloid deposition defined by longitudinal amyloid imaging with Pittsburgh compound B (PIB): (1) PIB-negative at baseline and follow-up (PIB(-) ; normal), (2) PIB-negative at baseline but PIB-positive at follow-up (PIB converters; early preclinical AD), and (3) PIB-positive at baseline and follow-up (PIB(+) ; preclinical AD).
methodsCognitively normal individuals (n = 164) who had undergone baseline PIB scan and CSF collection within 1 year of each other and at least 1 additional PIB follow-up were included. Amyloid status was defined dichotomously using an a priori mean cortical cutoff.
resultsPIB converters (n = 20) at baseline exhibited significantly lower CSF Aβ42 compared to those who remained PIB-negative (n = 123), but higher compared to the PIB(+) group (n = 21). A robust negative correlation (r = -0.879, p = 0.0001) between CSF Aβ42 and absolute (but subthreshold) PIB binding was observed during this early preclinical stage. The negative correlation was not as strong once individuals were PIB-positive (r = -0.456, p = 0.038), and there was no correlation in the stable PIB(-) group (p = 0.905) or in the group (n = 10) with early symptomatic AD (p = 0.537).
interpretationCSF Aβ42 levels are tightly coupled with cortical amyloid load in the earliest stages of preclinical AD, and begin to decrease dramatically prior to the point when an abnormal threshold of cortical accumulation is detected with amyloid imaging. Ann Neurol 2016;80:379-387.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.